Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.26 below Heron Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 376 other companies have achieved higher Quick Ratio than Heron Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 2132, from total ranking in the second quarter 2026 at 2329.

Explain Quick Ratio?
How much Cash & cash equivalents HRTX�s has?
What are HRTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HRTX/financial-strength

https://api.csimarket.com/api/v1/companies/HRTX/fundamentals

https://api.csimarket.com/api/v1/companies/HRTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

HRTX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	0.16 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-57.74 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.26	Subscribe	Subscribe	Subscribe	Subscribe
HRTX's Total Ranking	# 2132	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-2.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-63.73 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 377
Healthcare Sector	# 691
Overall Market	# 2132

Quick Ratio Statistics
High	Average	Low
14.61	3.98	0.16
(Dec 31 2012)		(Jun 30 2025)

Financial Statements
Heron Therapeutics Inc 's Current Liabilities	$ 90 Millions	Visit HRTX's Balance sheet
Heron Therapeutics Inc 's Cash & cash equivalent	$ 23 Millions	Visit HRTX's Balance sheet
Source of HRTX's Sales		Visit HRTX's Sales by Geography

Cumulative Heron Therapeutics Inc 's Quick Ratio

HRTX's Quick Ratio for the trailling 12 Months

HRTX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-30.23 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-12.9 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.49	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4076	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	0.04 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-15.14 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to HRTX Financial Strength Comparisons >> Go to Compare HRTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $89.85 millions, cumulative Quick Ratio decreased to 0.49 below the Heron Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Heron Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3949 to 4076.

Explain Quick Ratio?
How much Cash & cash equivalents HRTX�s has?
What are HRTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 439
Healthcare Sector	# 905
Within the Market	# 4076

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.37	3.58	0.35
(Dec 31 2012)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Ionis Pharmaceuticals Inc	0.68	$ 296.303 Millions	$ 435.292 Millions
Liquidia Corporation	0.68	$ 396.091 Millions	$ 585.397 Millions
Bristol myers Squibb Company	0.67	$ 12,581.000 Millions	$ 18,753.000 Millions
Harrow Inc	0.66	$ 75.336 Millions	$ 114.224 Millions
Supernus Pharmaceuticals inc	0.62	$ 176.171 Millions	$ 285.397 Millions
Axsome Therapeutics Inc	0.62	$ 313.859 Millions	$ 509.719 Millions
Travere Therapeutics Inc	0.59	$ 123.542 Millions	$ 210.912 Millions
Clene Inc	0.58	$ 9.887 Millions	$ 17.114 Millions
Zoetis Inc	0.57	$ 1,533.000 Millions	$ 2,682.000 Millions
Inovio Pharmaceuticals Inc	0.56	$ 49.786 Millions	$ 89.467 Millions
Organon and Co	0.55	$ 1,455.000 Millions	$ 2,652.000 Millions
Medicus Pharma Ltd	0.52	$ 5.020 Millions	$ 9.743 Millions
Gossamer Bio Inc	0.51	$ 51.189 Millions	$ 99.945 Millions
Bausch Health Companies Inc	0.51	$ 2,485.000 Millions	$ 4,895.000 Millions
Neonc Technologies Holdings Inc	0.49	$ 10.966 Millions	$ 22.241 Millions
Avenue Therapeutics Inc	0.47	$ 1.520 Millions	$ 3.210 Millions
Royalty Pharma Plc	0.46	$ 544.857 Millions	$ 1,179.003 Millions
Zymeworks Inc	0.45	$ 100.464 Millions	$ 223.931 Millions
Organogenesis Holdings Inc	0.45	$ 21.326 Millions	$ 47.649 Millions
Inmed Pharmaceuticals Inc	0.43	$ 1.140 Millions	$ 2.673 Millions
Kiniksa Pharmaceuticals International Plc	0.43	$ 81.660 Millions	$ 191.855 Millions
Syndax Pharmaceuticals Inc	0.40	$ 146.094 Millions	$ 361.833 Millions
Vanda Pharmaceuticals Inc	0.40	$ 62.038 Millions	$ 154.980 Millions
Kura Oncology Inc	0.39	$ 57.937 Millions	$ 148.730 Millions
Ultragenyx Pharmaceutical Inc	0.39	$ 150.000 Millions	$ 389.000 Millions
Biomarin Pharmaceutical Inc	0.38	$ 736.007 Millions	$ 1,913.942 Millions
Earth Science Tech Inc	0.38	$ 1.009 Millions	$ 2.639 Millions
Aurinia Pharmaceuticals Inc	0.36	$ 45.792 Millions	$ 127.629 Millions
Merck and Co Inc	0.34	$ 9,650.000 Millions	$ 28,801.000 Millions
Cytodyn inc	0.33	$ 16.359 Millions	$ 49.700 Millions

Date modified: 2026-11-11T13:46:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.